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Objective Adjunctive anticonvulsant medications may benefit some individuals with schizophrenia, however data on
adjunct anticonvulsants in older adults with schizophrenia is limited. This prospective, 12-week open label study evaluated
adjunct extended-release valproate semisodium (divalproex) in 20 older adults with schizophrenia.
Methods The study was conducted at an academic psychiatry clinic in the mid-western United States. Participants were
self-referred from posted advertisements or referred by clinic practitioners. Extended-release valproate semisodium was
added onto antipsychotic treatment. Individuals with active substance use disorders or active significant medical comorbidity
were excluded. Primary outcome measures included the Positive and Negative Syndrome Scale (PANSS), Geriatric
Depression Scale (GDS) and Global Assessment Scale (GAS). Tolerability was evaluated via patient self-reported side
effects, change from baseline in body weight and change on abnormal movement scales.
Results Patients (mean age 61 years, range 49.8–79.2 years) had significant reductions in psychosis scores as measured by
the Positive and Negative Syndrome Scale (PANSS) p< 0.01, as well as in global functioning as measured by the Global
Assessment Scale (GAS) p< 0.01 and depression as measured by the Geriatric Depression Scale (GDS) p< 0.05. Mean dose
of extended-release valproate semisodium was 587.50 mg/day SD 247.02. Extended-release valproate semisodium was
well tolerated in this older adult population. The primary adverse effect was sedation, which appeared to be relatively dose
and titration-speed dependent. Weight change was not significant.
Conclusion While extended-release valproate semisodium appears efficacious and well tolerated in older adults with
schizophrenia, data from larger, controlled trials is needed. Copyright # 2007 John Wiley & Sons, Ltd.key words — schizophrenia; valproate semisodium; elderly; anticonvulsantsINTRODUCTION
In clinical settings anticonvulsants are sometimes
utilized to augment treatment among individuals with
schizophrenia (Citrome et al., 2000), and there are
reports suggesting that augmentation anticonvulsant*Correspondence to: Dr M. Sajatovic, Department of Psychiatry,
University Hospitals of Cleveland, 11100 Euclid Avenue, Cleve-
land, OH 44106, USA. E-mail: martha.sajatovic@uhhs.com
Copyright # 2007 John Wiley & Sons, Ltd.therapy may improve schizophrenia symptoms (Wassef
et al., 2000; Casey et al., 2003; Citrome et al., 2004).
The issue of older adults with schizophrenia has
gained attention due to the growing proportion of
elderly world-wide (CDC, 2004; Jeste et al., 1999). In
geropsychiatric settings up to 65% of older adults with
schizophrenia/schizoaffective disorder receive antic-
onvulsant medication (Sajatovic et al., 2004). Although
utilization of anticonvulsants, valproate semisodium
in particular, is routinely seen in clinical settings, how
this augmentation specifically benefits older adultsReceived 21 December 2006
Accepted 4 May 2007
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of a prospective trial of adjunctive extended-release
valproate semisodium (divalproex) therapy focused on
older adults with schizophrenia. We hypothesized that
adjunctive extended-release valproate semisodium
would be well-tolerated and associated with improve-
ments in symptoms, level of functioning, and general
health status.METHODS
This was extended-release open-label, 12-week
prospective trial of add-on valproate semisodium
therapy in 20 older adults with schizophrenia as
confirmed by the Mini International Neuropsychiatric
Interview (MINI; Sheehan et al., 1998). The study was
conducted at an academic psychiatry clinic in the
mid-western United States. Participants were recruited
in response to self- referrals from posted advertise-
ments and by referrals from mental health prac-
titioners at the academic clinic and a nearby
community mental health clinic. Individuals were
considered sub-optimally responsive to current anti-
psychotic medications if, based upon either self-report
or report of care providers, they had remaining
symptoms of schizophrenia that either affected their
ability to meet daily needs or their ability to interact
with others. All patients provided written informed
consent, and the study was approved by the local
institutional review board (IRB). Eligible subjects
were receiving antipsychotic medications for the
treatment of schizophrenia. Individuals with acute
medical illness, including those positive for Hepatitis
C, and those with active substance abuse were exclu-
ded. Individuals were only considered for participa-
tion if they had not received a valproate trial in the
past.
Enrolled individuals received adjunctive, open-
label valproate semisodium, initially started as val-
proate semisodium delayed-release 250 mg at bedtime
for two weeks, then changed to valproate semisodium
extended-release 500 mg at bedtime. Medication was
administered on an outpatient/ambulatory basis, and
adjusted as tolerated to target serum levels of 50–
100mg/mL. In cases where sedation or other side
effects occurred, dosage was reduced. Valproate semi-
sodium was prescribed in a single dose at bedtime.
The primary outcome measure was change from
baseline on a schizophrenia psychopathology assess-
ment, the Positive and Negative Syndrome Scale
(PANSS; Kay et al., 1987). Secondary outcomes
included change from baseline on a measure ofCopyright # 2007 John Wiley & Sons, Ltd.depression [the Geriatric Depression Scale (GDS:
Yesavage et al., 1982)], overall change in functioning
[Global Assessment Scale (GAS; Guy, 1976)] and
change in general health status [Short Form 36 Health
Survey (SF-36; Ware and Sherbourne, 1992)] and
cognitive status [Mini-Mental State Examination
(MMSE; Folstein et al., 1975)]. Extrapyramidal
symptoms were evaluated with the Abnormal Invo-
luntary Movement Scale (AIMS; Guy, 1976), the
Barnes Akathisia Scale (BAS; Barnes, 1989), and the
Simpson Angus Neurological Rating Scale (SAS;
Simpson and Angus, 1970).
All rating scale measures were conducted at
baseline, and at weeks 2,4,8 and 12 (end of study).
All patients had baseline assessment of basic serum
chemistry, metabolic profile, complete blood count
(CBC) with differential, vital signs, weight and
electrocardiogram. Vital signs and weight were asses-
sed at each study visit, and laboratory testing was
repeated again at end of study. Serum total valproate
levels were obtained by week 4, and at weeks 8 and 12.
Efficacy and safety results were calculated using
descriptive statistics. Scores for each rating scale over
time were evaluated using paired t-tests comparing
baseline and last available assessment of each mea-
sure. The intent-to-treat (ITT) population was defined
as individuals who received at least one dose of
valproate semisodium.RESULTS
Clinical characteristics of the sample
Table 1 illustrates sample baseline clinical character-
istics. Mean age was 61.5 years, SD 9.4, range
49.8–79.2 years. This was a chronically mentally ill
population, with mean age of 31.2 SD 18.1 years
at illness onset, and mean duration of illness of
29.2 13.3 years. The majority of patients had mode-
rate baseline symptoms of schizophrenia with a mean
PANSS score of 72.65 17.17, mean PANSS negative
sub-scale 18.20 6.30, and mean PANSS positive
subscale 17.90 3.51. This was a non-demented
population with a mean MMSE score of 27.50 1.73,
range 24–30.
Concomitant antipsychotic medications included
risperidone (n¼ 6, 33%), olanzapine (n¼ 4, 20%),
aripiprazole (n¼ 4, 20%), quetiapine (n¼ 3, 15%),
and clozapine (n¼ 1, 5%). One individual was on both
olanzapine and long-acting injectable risperidone, and
one individual was on both olanzapine and aripipra-
zole. There were four individuals on conventionalInt J Geriatr Psychiatry 2008; 23: 142–147.
DOI: 10.1002/gps
Table 1. Clinical characteristics of 20 older adults with schizophrenia who received adjunctive (extended-release) valproate semisodium
therapy
Variable Value N (%) Baseline to LOCF t-test p-value
Sex
Male 4 (20) n/a
Female 16 (80)
Age, years
MeanSD 61.1 9.6 n/a
Range 49.8–79.2
Ethnicity




Olanzapine 4 (20) n/a




Most common comorbid medical conditions
Hypertension 9 (45)
Diabetes 8 (40) n/a
Hyperlipidemia 6 (30)
Coronary Artery Disease 5 (20)
Chronic Renal Insufficiency 3 (15)
Morbid Obesity 3 (15)
Arthritis 3 (15)
Baseline PANSS
MeanSD 72.65 17.17 <0.001
Baseline GDS
MeanSD 15.72 4.56 0.017
Baseline GAS
MeanSD 46.9 14.34 <0.001
Baseline MMSE
MeanSD 27.5 1.73 0.585
Baseline SF-36
Mean PCSSD 35.2 10.05 0.569
Mean MCSSD 37.1 13.74 0.027
Dose of valproate semisodium mg/day at end of study
MeanSD 587.5 247.02 n/a
Range 250–1000
GAS¼Global Assessment of Functioning; GDS¼Geriatric Depression Scale; MMSE¼Mini Mental State Examination; PANSS¼
Positive and Negative Syndrome Scale; SF-36¼ 36-item Short Form Health Survey; PCS¼ Physical Composite; MCS¼Mental Composite.
*Some individuals on more than one antipsychotic compound.
144 m. sajatovic ET AL.antipsychotics (haloperidol n¼ 3, thiothixene n¼ 1),
including two on long-acting injectable haloperidol.
During the study there were five individuals who had
reductions in their antipsychotic medication dosing
(four individuals to reduce extrapyramidal symptoms
(haloperidol n¼ 2, thiothixene n¼ 1, risperidone
n¼ 1), and one individual on olanzapine to attempt
to reduce propensity for weight gain). Baseline
chlorpromazine (CPZ) equivalents (Fuller and Saja-
tovic, 2007) for individuals that were on oral anti-
psychotic medications was 375 CPZ equivalents/day
(SD 268.3, range 100–1,250 CPZ equivalents/day),Copyright # 2007 John Wiley & Sons, Ltd.while endpoint CPZ equivalents was 303 CPZ equi-
valents/day (SD 288.5), a difference that was not
statistically significant (p> 0.05).
Comorbid medical conditions were common, and
included hypertension (n¼ 9, 45%), diabetes (n¼ 8,
40%), hyperlipidemia/cholesterolemia (n¼ 6, 30%),
coronary artery disease (n¼ 5, 20%), chronic renal
insufficiency (n¼ 3, 15%), arthritis (n¼ 3, 15%),
morbid obesity (n¼ 3, 15%) and one individual each
(5%) with chronic pain, chronic osteomyelitis, GERD,
Parkinson’s disease, hypothyroidism, sarcoidosis and
seizure disorder.Int J Geriatr Psychiatry 2008; 23: 142–147.
DOI: 10.1002/gps
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Significant improvements were seen in PANSS
( p< 0.001), GAS ( p< 0.001) and GDS ratings
( p< 0.02). The MMSE scores did not change signifi-
cantly ( p¼ 0.585). There was no significant difference
in the Physical Composite Score (PCS) subscale of the
SF-36 (p¼ 0.569), but there was a significant
improvement in the Mental Composite Score
(MCS) subscale ( p< 0.05).
Tolerability:
Extended-release valproate semisodium was fairly
well tolerated in this population. Five patients pre-
maturely discontinued study medication due to non-
adherence with study medication in 4 individuals and
adverse medical event unrelated to study medication
(groin abscess) in one individual. Adverse effects
included sedation in six individuals (30%), and more
rarely constipation, dry mouth, orthostasis (one indi-
vidual, 5% for each). Mean body weight was 89.4
19.8 kg at baseline and 91.6 21.4 kg at endpoint
( p¼ 0.21). EPS ratings showed significant improve-
ment in AIMS scores ( p< 0.05) and BAS scores
( p< 0.05), but no significant change in SAS scores
( p¼ 0.20).
Mean daily dose of extended-release valproate
semisodium was 587.5 247.02 mg/day, range 250–
1000 mg/day. Mean serum level at study end-point
was 40.86 25.29mg/mL. There were no significant
changes on laboratory testing or in vital signs.
DISCUSSION
This open-label, pilot study suggests that adjunctive
extended-release valproate semisodium is relatively
well tolerated and may be associated with improve-
ments in psychopathology among older adults with
schizophrenia. While 25% of individuals in the study
presented here dropped out prematurely, none did so
because of adverse events related to study medication.
Recent large-scale treatment trials involving mixed
age patients with schizophrenia (Lieberman et al., 2005;
Jones et al., 2006) demonstrate early medication
discontinuation or medication switching rates in the
order of 46–74%. Low persistence with medication
treatment appears to be a pervasive problem among
populations with schizophrenia that complicates
interpretation of studies of schizophrenia treatments.
Casey and colleagues (2003) conducted a double
blind, randomized study of valproate semisodium with
an antipsychotic agent for mixed age individuals withCopyright # 2007 John Wiley & Sons, Ltd.schizophrenia. Patients were treated with either olan-
zapine or risperidone monotherapy, valproate semi-
sodium plus olanzapine or valproate semisodium plus
risperidone for 28 days. Improvements from baseline
were observed in all treatment groups, with statisti-
cally significant treatment differences favoring com-
bination treatments on the Positive and Negative
Syndrome Scale (PANSS) total score by day 3 and
persisting to day 21 ( p< 0.05), but not to day 28
(p¼ 0.108). An 84-day study failed to replicate the
apparent early robust response to adjunct valproate
(http://www.clinicalstudyresults.org/documents/company-
study_782_0.pdf.) Similarly, a Cochrane Database
review (Basan et al., 2004) that examined the effec-
tiveness of valproate as an adjunct to antipsychotic
medications in mixed age schizophrenia populations
noted no significant effect of using valproate as an
adjunct to antipsychotic therapy. Randomized, con-
trolled trials with valproate semisodium have also
been conducted to evaluate effects on behavioral
symptoms in elderly dementia populations (Porsteins-
son et al., 2001; Sival et al., 2002; Tariot et al., 2005).
However, the findings are consistent with the rela-
tively unpromising results across varying psychotro-
pic compounds for symptoms of dementia (Sink et al.,
2005).
In spite of the inconsistent/negative randomized,
controlled trials (RCTs) in general schizophrenia
populations, it has been suggested that valproate may
remain a useful adjunct in sub-populations with
schizophrenia who are sub-optimally responsive to
antipsychotic monotherapy or who have other atypical
presentations such as prominent mood or anxiety
symptoms or those with aggressive behavior (Basan
et al., 2004; Citrome et al., 2004; Stahl, 2004;
Townsend and Wilson, 2005; Gobbi et al., 2006).
Elderly individuals, who may be unusually sensitive to
adverse effects of antipsychotics, or those older adults
who have remaining symptoms even with antipsy-
chotic medication treatments may potentially benefit
from adjunctive valproate.
Individuals in the study reported here received
relatively modest doses of valproate semisodium
(mean dose 587.5 mg/day), considerably lower than
the doses reported in the study by Casey and colle-
agues (2003). In the mixed age trial conducted by
Casey and colleagues (2003), 29% of individuals
experienced somnolence, which was the most com-
mon reported side effect of all treatments. Consistent
with the report by Basan and colleagues (2004),
sedation was the most common adverse effect (30%
of individuals) among older adults in this study
who received adjunct valproate semisodium. In someInt J Geriatr Psychiatry 2008; 23: 142–147.
DOI: 10.1002/gps
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were limited by subjective experience of sedation or
tiredness.
The mechanism of action by which adjunct antic-
onvulsant medications may be helpful in refractory or
resistant psychosis is unclear. It has been suggested
that diminished prefrontal cortical dopamine activity
may contribute to impaired cognition among individ-
uals with schizophrenia, and that use of adjunct anti-
convulsant therapy may enhance release of cortical
dopamine. Ichikawa and colleagues (2005) recently
reported that valproate, when combined with anti-
psychotics, produces greater increases in prefrontal
cortical dopamine release than either type of drug
alone via a mechanism dependent upon 5HT (1A)
receptor activation. Alternatively, Wassef and col-
leagues (1999, 2003) have suggested that abnormal-
ities in the gamma-aminobutyric acid (GABA) neuro-
transmitter system implicated in the pathogenesis of
schizophrenia, may be at least partially corrected by
GABA-ergic agonists such as valproate.
While the MMSE did not demonstrate change with
valproate semisodium therapy in this non-demented
population, it is possible that more subtle improve-
ments in cognition could have been at least in part
demonstrated by changes seen on the other psycho-
pathology ratings such as the PANSS. It is known that
valproate co-administration can increase plasma
concentrations and area under the plasma concen-
tration-time curve (AUC) of the anticonvulsants lamo-
trigine and carbamazepine, lorazepam and some anti-
depressants (Calvo et al., 1986; Anderson, 1998;
Fuller, 2007). Adjunctive valproate therapy has been
reported to have minimal effects on steady state serum
levels of some antipsychotic compounds (Citrome
et al., 2005; Fuller, 2007).
In this study, older adults were initially begun on
valproate semisodium delayed release (DR) and then
transitioned to valproate semisodium extended-
release (ER). Citrome and colleagues (2004) reported
on the safety, efficacy and tolerability of switching
from valproate semisodium DR formulation to
once-daily dosing with valproate semisodium ER in
30 individuals with schizophrenia. Patients were
converted from valproate semisodium DR to ER
formulation on a 1.0:1.0 basis (rounded up to the
nearest 500-mg increment) for initial plasma valproate
levels 85mg/mL and on a 1.0: 1.2 basis for initial
plasma levels of <85 g/mL (Citrome et al., 2004).
Baseline and endpoint changes on psychopathology
and adverse event ratings scales (Positive and Nega-
tive Syndrome (PANSS) and Udvalg for Klinishke
Undersogelser Side Effect Rating Scale (UKU)) wereCopyright # 2007 John Wiley & Sons, Ltd.minimally changed and baseline and end-point serum
trough valproate semisodium levels were 80.1 and
73.1 respectively, suggesting that switch-over was
well tolerated and that the differences in serum levels
were of small magnitude.
Consistent with the procedures of the small trial
reported here, it appears that individuals receiving
valproate semisodium DR can be readily converted to
valproate semisodium ER on a 1:1, or perhaps a
1.0:1.2 basis. In the case of older adults with schi-
zophrenia, the once-daily dosing formulation was
more easily remembered and accommodated into an
individual’s life-style than multiple-dosed valproate
semisodium.
The findings of this study must be interpreted
cautiously given the limitations of small sample size,
open-label, add-on design and lack of a control or
comparator group. Additionally, the sample mean age
of approximately 61 years is not representative of the
‘old-old’ populations seen in some geriatric-focused
studies, and results cannot necessarily be extrapolated
to the oldest geriatric populations with schizophrenia.
In conclusion, this uncontrolled prospective study
of adjunctive valproate semisodium in older adults
with schizophrenia suggests that the addition of val-
proate semisodium to antipyschotic treatment may be
associated with improvement in symptoms. Larger,
controlled studies are needed to further evaluate the
effects of adjunctive valproate semisodium on symp-
toms of schizophrenia in older adult populations.
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